Article

Ira Klein, MD, Discusses Quality Measures in Oncology

Ira Klein, MD, MBA, FACP, chief medical officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology.

Ira Klein, MD, MBA, FACP, chief medical officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology. Dr Klein says that measurement is a driver for value and healthcare in the future. Quality measures, such as QOPI and HEDIS, allow oncologists to measure how they should be rewarded and recognized for making improvement.

Related Videos
Shawn Griffin, MD, sitting for a video interview
Christine Funke, MD
John Michael O'Brien, PharmD, MPH
Kathi Henson, MBA, sitting for a video interview
Mike Fazio, Navista, Cardinal Health
Dr Mingyang Song
Fran Gregory, PharmD, MBA, sitting for a video interview
Casey Koch, PharmD, sitting for a video interview
Dr K. Vish Viswanath
Related Content
The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com
April 29th 2025

New Developments Warrant Rethinking HCC Transplant Criteria

Jared Kaltwasser
Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.
managed care cast logo
April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD
On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
senior scientist | Image credit: Ohio State University
April 28th 2025

Proving the Concept: A Sampler of Early-Stage Science at AACR 2025

Mary Caffrey
From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com
April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD
When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
April 23rd 2025

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

AJMC Contributor
Even with prevention measures and timely, aggressive intervention, tumor lysis syndrome (TLS) remains life-threatening, as a case study in small cell lung cancer (SCLC) illustrates.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo